The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
Abstract
PURPOSE: Few chemotherapy agents are active in leiomyosarcoma (LMS), particularly LMS that has progressed after doxorubicin treatment. We sought to determine the response to gemcitabine plus docetaxel among patients with LMS. PATIENTS AND METHODS: Patients with unresectable LMS of uterine (n = 29) or other (n = 5) primary sites who did not respond to zero to two prior chemotherapy regimens were enrolled onto a phase II study of gemcitabine 900 mg/m 2 intravenously (IV) on days 1 and 8 plus docetaxel 100 mg/m 2 IV on day 8 with granulocyte colony-stimulating factor given subcutaneously on days 9 to 15, delivered every 21 days. Patients with prior pelvic radiation received 25% lower doses of both agents. Gemcitabine was delivered over 30 or 90 minutes in cycles 1 and 2 and by 90-minute infusion in all subsequent cycles. Pharmacokinetic studies assessed in vivo differences in gemcitabine concentrations with different rates of infusion. RESULTS: Thirty-four patients (median age, 55 years; range, 32 to 74 years) have enrolled. Fourteen had received prior pelvic radiation. Sixteen of 34 patients had progressed after doxorubicin-based therapy; 18 had no prior chemotherapy. Among 34 patients, complete response was observed in three patients and partial response in 15, for an overall response rate of 53% (95% confidence interval, 35% to 70%). Seven patients had stable disease. Fifty percent of patients previously treated with doxorubicin responded. Hematologic toxicity was common (neutropenia: grade 3, 15%; grade 4, 6%; thrombocytopenia: grade 3, 26%; grade 4, 3%), but neutropenic fever (6%) and bleeding events (0%) were rare. The median time to progression was 5.6 months (range, 4 to 10 months). CONCLUSION: Gemcitabine plus docetaxel is tolerable and highly active in treated and untreated patients with LMS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1991) · PubMed · Cited by 876
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
Abbruzzese, J. L., Grunewald, R., Weeks, E. A., Gravel, D., Adams, T., Nowak, B., Mineishi, S., Tarassoff, P., Satterlee, W., & Raber, M. N. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.491 · Cited by 759
Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol
Ringel, I., & Horwitz, S. B. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.4.288 · Cited by 677
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
Heinemann, V, Xu, Y. Z., Chubb, S., Sen, A., Hertel, L. W., Grindey, G. B., & Plunkett, W. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09518-5 · Cited by 399
Gemcitabine: preclinical pharmacology and mechanisms of action.
Plunkett, W. K., Huang, P., Searcy, C. E., & Gandhi, V. V. (1996) · PubMed · Cited by 396
Valero, V, Holmes, F. A., Walters, R. S., Theriault, R. L., Esparza, L., Fraschini, G., Fonseca, G. A., Bellet, R. E., Buzdar, A. U., & Hortobagyi, G. N. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2886 · Cited by 386
Anderson, H., Lund, B., Bach, F., Thatcher, N., Walling, J., & Hansen, H. H. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1821 · Cited by 374
Omura, G. A., Major, F. J., Blessing, J. A., Sedlacek, T. V., Thigpen, J. T., Creasman, W. T., & Zaino, R. J. (1983) · Cancer · doi:10.1002/1097-0142(19830815)52:4<626::aid-cncr2820520409>3.0.co;2-e · Cited by 355
Ravdin, P. M., Burris, H. A., Cook, G., Eisenberg, P., Kane, M., Bierman, W. A., Mortimer, J., Genevois, E., & Bellet, R. E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2879 · Cited by 317
Preclinical characteristics of gemcitabine
Plunkett, W., Huang, P., & Gandhi, V. (1995) · Anti-Cancer Drugs · doi:10.1097/00001813-199512006-00002 · Cited by 283
Patel, S. R., Gandhi, V., Jenkins, J., Papadopolous, N., Burgess, M. A., Plager, C., Plunkett, W., & Benjamin, R. S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3483 · Cited by 247
Grunewald, R., Abbruzzese, J. L., Tarassoff, P., & Plunkett, W. (1991) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685109 · Cited by 244
Gatzemeier, U., Shepherd, F. A., Le Chevalier, T., Weynants, P., Cottier, B., Groen, H. J. M., Rosso, R., Mattson, K., Cortes-Funes, H., Tonato, M., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00444-0 · Cited by 241
Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
Francis, P. A., Rigas, J. R., Kris, M. G., Pisters, K. M., Orazem, J. P., Woolley, K. J., & Heelan, R. T. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.6.1232 · Cited by 216
Grunewald, R., Kantarjian, H. M., Keating, M., Abbruzzese, J. L., Tarassoff, P. G., & Plunkett, W. (1990) · PubMed · Cited by 209
Verweij, J., Lee, S. M., Ruka, W., Buesa, J., Coleman, R., van Hoessel, R., Seynaeve, C., di Paola, E. D., van Glabbeke, M., Tonelli, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2081 · Cited by 171
for the ECTG (Early Clinical Trials Group of the EORTC), Cerny, T., Kaplan, S., Pavlidis, N., Schöffski, P., Epelbaum, R., van Meerbeek, J., Wanders, J., Franklin, H., & Kaye, S. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.311 · Cited by 160
Kunitoh, H., Watanabe, K., ONOSHI, T., Furuse, K., Niitani, H., & Taguchi, T. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1649 · Cited by 136
Smith, H. O., Blessing, J. A., & Vaccarello, L. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2001.6482 · Cited by 43
Cited by
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Soft-Tissue Sarcomas in Adults
Clark, M. A., Fisher, C., Judson, I., & Thomas, J. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041866 · Cited by 907
Maki, R. G., Wathen, J. K., Patel, S. R., Priebat, D. A., Okuno, S. H., Samuels, B., Fanucchi, M., Harmon, D. C., Schuetze, S. M., Reinke, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4117 · Cited by 742
Self-citationSoft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, J. M., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0025 · Cited by 736
Metadata
- Authors
- Hensley, M. L., Maki, R., Venkatraman, E., Geller, G., Lovegren, M., Aghajanian, C., Sabbatini, P., Tong, W., Barakat, R., & Spriggs, D. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-06-15
- Volume
- 20
- Issue
- 12
- Pages
- 2824-2831
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2161170571
- Cited by
- 683
- References
- 20
- FWCI
- 18.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.